Get the Stockscreener App
9.03
4.04%
-0.38
Oric Pharmaceuticals Inc stock is traded at $9.03, with a volume of 808.33K.
It is down -4.04% in the last 24 hours and up +90.91% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$9.41
Open:
$9.26
24h Volume:
808.33K
Relative Volume:
0.71
Market Cap:
$830.88M
Revenue:
-
Net Income/Loss:
$-119.87M
P/E Ratio:
-4.989
EPS:
-1.81
Net Cash Flow:
$-109.90M
1W Performance:
-7.38%
1M Performance:
+90.91%
6M Performance:
+9.45%
1Y Performance:
+21.37%
1-Day Range:
$9.00
$9.51
1-Week Range:
$9.00
$10.04
52-Week Range:
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
9.03 | 830.88M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 3.4%Should You Sell? - MarketBeat
(ORIC) Trading Report - news.stocktradersdaily.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down Following Insider Selling - MarketBeat
Millennium Management LLC Has $223,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Research Analysts Issue Forecasts for ORIC FY2026 Earnings - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 2,976 Shares - MarketBeat
Oric Pharmaceuticals Elects Directors at Annual Meeting - TipRanks
What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now? - sharewise
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down After Insider Selling - Defense World
Dominic Piscitelli Sells 2,600 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock - MarketBeat
Bank of America Corp DE Acquires 28,570 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Millennium Management LLC Trims Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Brokers Issue Forecasts for ORIC FY2026 Earnings - Defense World
Insider Sell: Dominic Piscitelli Sells Shares of ORIC Pharmaceuticals Inc (ORIC) - GuruFocus
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of “Buy” from Analysts - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Buy" from Analysts - MarketBeat
Transcript : ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - marketscreener.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpStill a Buy? - MarketBeat
Two Sigma Investments LP Decreases Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Bank of America Corp DE - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up – Here’s What Happened - Defense World
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 7.6%Still a Buy? - MarketBeat
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - mx.advfn.com
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharmaceuticals Expands Oncology Team with 45,600 Equity Grants for New Clinical Specialists - Stock Titan
ORIC Pharmaceuticals, Inc. announced that it has received $124.999983 million in funding from a group of investors - marketscreener.com
Cantor Fitzgerald Estimates ORIC FY2025 Earnings - MarketBeat
Two Sigma Investments LP Decreases Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 3.5%What's Next? - MarketBeat
Two Sigma Advisers LP Acquires 8,300 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Viking Invests $125 Million in ORIC Pharmaceuticals PIPE Financing - Global Legal Chronicle
Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know - MSN
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownTime to Sell? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
H.C. Wainwright maintains buy rating on ORIC Pharmaceuticals stock By Investing.com - Investing.com Nigeria
BNP Paribas Financial Markets Buys New Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Wedbush Reiterates Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial - MSN
Viking in PIPE Investment in ORIC Pharmaceuticals - Cleary Gottlieb
ProShare Advisors LLC Increases Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ORIC) - MarketBeat
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):